Thermo Fisher Scientific (TMO) Accumulated Expenses (2009 - 2026)

Thermo Fisher Scientific has disclosed Accumulated Expenses across 18 years of filings, most recently posting $1.6 billion for Q1 2026.

• Quarterly Accumulated Expenses rose 10.29% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 10.29% YoY) and the FY2025 annual result came in at $2.0 billion, changed 0.35% from the prior year.
• Accumulated Expenses declined to $1.6 billion in Q1 2026, from $2.0 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.1 billion in Q4 2022 and troughed at $1.3 billion in Q2 2023.
• A 5-year average of $1.6 billion and a median of $1.6 billion in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses retreated 23.93% — and 2024, when it increased 24.86%.
• Tracing TMO's Accumulated Expenses over 5 years: stood at $2.1 billion in 2022, then slipped by 23.82% to $1.6 billion in 2023, then grew by 24.56% to $2.0 billion in 2024, then increased by 0.35% to $2.0 billion in 2025, then dropped by 21.55% to $1.6 billion in 2026.
• Business Quant data shows TMO's Accumulated Expenses at $1.6 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.9 billion in Q3 2025.